<DOC>
	<DOCNO>NCT03070990</DOCNO>
	<brief_summary>The objective study ass safety , tolerability pharmacokinetics enfortumab vedotin ( ASG-22CE ) administer intravenously Japanese subject locally advance metastatic urothelial carcinoma . This study also assess immunogenicity define incidence anti-drug antibody ( ADA ) anti-tumor activity enfortumab vedotin ( ASG-22CE ) administer intravenously Japanese subject locally advance metastatic urothelial carcinoma .</brief_summary>
	<brief_title>A Study Enfortumab Vedotin Japanese Subjects With Locally Advanced Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description>All subject receive single 30 minute intravenous ( IV ) infusion enfortumab vedotin ( ASG-22CE ) weekly 3 week every 4 week ( i.e. , Days 1 , 8 , 15 ) . A cycle 28 day .</detailed_description>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Subject must histologically confirm , locally advanced ( TNM classification T3b N ; T N23 ) metastatic Transitional Cell Carcinoma Urothelium ( TCCU ) ( i.e. , cancer bladder , renal pelvis , ureter , urethra ) . Subjects Urothelial Carcinoma squamous differentiation mixed cell type eligible . Subject must able submit tumor tissue sample Nectin4 expression analysis central laboratory . Subject must fail least one prior chemotherapy regimen advance disease . Urothelial bladder cancer subject require fail prior chemotherapy regimen consider unfit cisplatinbased chemotherapy . Subject must measurable disease accord Response Evaluation Criteria Solid Tumor ( RECIST ) ( version 1.1 ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Preexisting sensory neuropathy Grade ≥ 2 . Preexisting motor neuropathy Grade ≥ 2 . Uncontrolled central nervous system metastasis require active treatment . Any anticancer therapy within 14 day prior first dose study drug . Subjects preexist immunotherapyrelated adverse event require high dos systemic steroid eligible .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Enfortumab vedotin</keyword>
	<keyword>ASG-22CE</keyword>
	<keyword>ASG-22ME</keyword>
	<keyword>Metastatic Urothelial Cancer</keyword>
</DOC>